Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of clinical pharmacology

• Publication date

  1993-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/j.1552-4604.1993.tb04706.xPMID 8366183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics of the quantitative Lp(a) lipoprotein trait

  2004cited by this paper
• Lipoprotein(a) reduction by N-acetylcysteine.

  1991cited by this paper
• N-acetylcysteine and immunoreactivity of lipoprotein(a)

  1991cited by this paper
• Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations.

  1991cited by this paper
• EFFECTIVE THERAPEUTIC MEASURES FOR REDUCING LIPOPROTEIN (A) IN PATIENTS WITH DYSLIPIDEMIA. LIPOPROTEIN (A) REDUCTION WITH SUSTAINED-RELEASE BEZAFIBRAT E

  1991cited by this paper
• Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.

  1990cited by this paper
• Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.

  1990cited by this paper
• Chapter 15 – Effectiveness of Diet and Drugs in the Treatment of Patients with Elevated Lp(a) Levels

  1990cited by this paper
• Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.

  1990cited by this paper
• Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.

  1990cited by this paper
• HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.

  1989cited by this paper
• Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

  1989cited by this paper
• The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.

  1989cited by this paper
• Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis.

  1989cited by this paper
• Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor

  1988cited by this paper
• Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

  1987cited by this paper
• Effect of fibric acid derivatives on blood lipid and lipoprotein levels.

  1987cited by this paper
• Lp(a) lipoprotein as a risk factor for myocardial infarction.

  1986cited by this paper
• Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.

  1985cited by this paper
• A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

  1978cited by this paper
• Serum lipids in angiographically assessed coronary atherosclerosis.

  1978cited by this paper
• Apolipoprotein A-II content of human plasma high density lipoproteins measured by radioimmunoassay.

  1977cited by this paper
• Lp(a) lipoprotein/pre‐ß1‐lipoprotein in Swedish middle‐aged males and in patients with coronary heart disease

  1975cited by this paper
• The structure of human high density lipoprotein and the levels of apolipoprotein A-I in plasma as determined by radioimmunoassay.

  1974cited by this paper
• Assay of total plasma apolipoprotein B concentration in human subjects.

  1974cited by this paper
• Lp(a) lipoprotein and pre‐β1‐lipoprotein in patients with coronary heart disease

  1974cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography

  year unknowncited by this paper

• A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques

  2026cites this paper
• Statins—Their Effect on Lipoprotein(a) Levels

  2025cites this paper
• Lipoprotein(a) and Chronic Kidney Disease: Insights into New Therapeutic Opportunities.

  2025cites this paper
• Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.

  2021cites this paper
• Pravastatin for lowering lipids.

  2020cites this paper
• Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.

  2019cites this paper
• Statins and Lp(a) – the plot thickens

  2019cites this paper
• Familial hypercholesterolaemia: identification and management

  2017cites this paper
• The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab[S]

  2017cites this paper
• Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.

  2017cites this paper
• PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role[S]

  2016cites this paper
• Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

  2016cites this paper
• Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

  2014cites this paper
• Effect of statins on lipoprotein (a) in dyslipidemic patients

  2014cites this paper
• Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms☆

  2013cites this paper
• Relationship between serum parathyroid hormone levels and lipid profile in non-diabetic hemodialysis patients.

  2012cites this paper
• Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!

  2010cites this paper
• Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

  2009cites this paper
• Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.

  2009cites this paper
• Pravastatin Sodium Tablets USP

  2009cites this paper
• Lipids in Health and Disease

  2008cites this paper
• Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.

  2006cites this paper
• Cardiovascular Disease: Strategies for Risk Assessment and Modification

  2006cites this paper
• Novel concepts of statin therapy for cardiovascular risk reduction in hypertension.

  2006cites this paper
• Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.

  2005cites this paper
• The Role of Nitric Oxide in Heart Failure

  2004cites this paper
• Statins and the Role of Nitric Oxide in Chronic Heart Failure

  2004cites this paper
• Lipids in Health and Disease

  2004cites this paper
• The Combination of Nebivolol plus Pravastatin is Associated with a More Beneficial Metabolic Profile Compared to that of Atenolol plus Pravastatin in Hypertensive Patients with Dyslipidemia: A Pilot Study

  2003influential citation
• Lipoprotein(a): An Emerging Cardiovascular Risk Factor

  2003cites this paper
• Long-term administration of pravastatin reduces serum lipoprotein(a) levels.

  2003cites this paper
• Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors

  2002cites this paper
• Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.

  2002cites this paper
• Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.

  2002cites this paper
• Long‐Term Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Primary Hypercholesterolemia

  2001cites this paper
• Porównanie skuteczności hipolipemicznej statyn i hormonalnej terapii zastępczej u kobiet z hipercholesterolemią po menopauzie

  2001cites this paper
• Lipoprotein (a) and stroke

  2000cites this paper
• Beneficial Effects of Statins in Coronary Artery Disease — Beyond Lowering Cholesterol

  2000cites this paper
• Effects of HMG-CoA reductase inhibitor on hemostasis.

  2000cites this paper
• Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates

  2000cites this paper
• PRODUCT MONOGRAPH

  2000cites this paper
• SIALIC ACID IN LIPOPROTEINS WITH A SPECIAL REFERENCE TO LOW DENSITY LIPOPROTEINS

  2000cites this paper
• Platelets and lipoprotein (a): a brief overview of their role in the pathogenesis of atherothrombosis.

  1999cites this paper
• Effects of Exercise on Lipoprotein(a)

  1999cites this paper
• Effects of Statins on Endothelium: Vasomotor Function, Inflammation, and Hemostasis

  1999cites this paper
• Should one routinely screen for lipoprotein(a)?

  1999cites this paper
• Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement.

  1998cites this paper
• Interactions among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified diets

  1998cites this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998cites this paper
• Review: Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease

  1997cites this paper
• Lipoprotein Lp(a) excess and coronary heart disease.

  1997cites this paper
• Effects of physical activity and diet on lipoprotein(a).

  1997cites this paper
• Platelet-dependent thrombin generation in patients with hyperlipidemia.

  1997cites this paper
• Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a).

  1997cites this paper
• Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women.

  1995cites this paper
• Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.

  1995cites this paper
• Once-daily pravastatin compared with dietary advice in patients with borderline and moderate primary hypercholesterolemia

  1995cites this paper
• Effect of simvastatin on Lp(a) concentrations

  1995cites this paper
• Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs

  1995cites this paper
• Drug and alternative therapies for hyperlipidemia.

  1994cites this paper